Diabetes Care
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Diabetes Care 31:S136-S139, 2008
DOI: 10.2337/dc08-s234
© 2008 by the American Diabetes Association
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Standl, E.
Right arrow Articles by Schnell, O.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Standl, E.
Right arrow Articles by Schnell, O.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Section I: Diabetes-What Is New in the Management and Understanding of the Disease?
Original Article

Insulin as a First-Line Therapy in Type 2 Diabetes

Should the use of sulfonylureas be halted?

Eberhard Standl, MD and Oliver Schnell, MD

From the Munich Diabetes Research Institute, Munich, Germany

Address correspondence and reprint requests to Eberhard Standl, Chairman, Munich Diabetes Research Institute, Kölner Pl.1, D-80804 Munich, Germany. E-mail: eberhard.standl@lrz.uni-muenchen.de

Abbreviations: ADA, American Diabetes Association • DPP, dipeptidyl peptidase • EASD, European Association for the Study of Diabetes • ESC, European Society of Cardiology • UKPDS, UK Prospective Diabetes Study

The first 300 words of the full text of this article appear below.


   INTRODUCTION
 
Because a tidal wave of type 2 diabetes is presently rolling on a global scale, owing to the ever-increasing prevalence of obesity along with overnutrition, increasing physical inactivity, and aging populations worldwide, the debate is still ongoing over the appropriate first-line therapy. Recently, the International Diabetes Federation and the American Diabetes Association (ADA)/European Association for the Study of Diabetes (EASD) suggested distinct treatment algorithms (Fig. 1) (1), which have sparked the discussion even further, although there is strong agreement that weight-regulating nutrition and a prudent lifestyle are the cornerstones of any treatment. Here, the pro and con discussion explores the use of insulin versus sulfonylureas as first-line pharmacotherapy.


Figure Removed (Available Only in the Full Text)
View larger version (19K):



  		Figure 1— ADA/EASD consensus: management of hyperglycemia in type 2 diabetes (1).

 

   HOW EFFECTIVE IS INSULIN AS A FIRST-LINE THERAPY?
 
Evidence base
The landmark UK Prospective Diabetes Study (UKPDS) has published evidence-based outcome results comparing the randomized addition of insulin or sulfonylurea treatment (with glibenclamide) to lifestyle therapy after diagnosis of type 2 diabetes (2). To make a long story short, no difference between these two treatment options was observed. Both gave a similar degree of (yet overall unsatisfactory) metabolic control long term and both reduced microvascular complications significantly, but failed to reduce macrovascular end points. Both therapies were burdened by significant weight gain and the risk of serious hypoglycemic episodes (2). These downsides appeared to be more marked with insulin therapy. So, based on these data, very little evidence exists that first-line insulin therapy is superior to sulfonylurea treatment, since no other long-term studies are available at present.

Limitations of present information
Insulin therapy in the UKPDS was not very well structured and was mainly based on long-acting insulin, which more or less has been abandoned. Newer concepts of insulin therapy have not been tested, e.g., combination therapies with intermediate-acting insulins or insulin analogs with flat action . . . [Full Text of this Article]


   PATHOGENETIC BACKGROUND
 

   SHOULD THE USE OF SULFONYLUREAS BE HALTED?
 
Evidence base
Treatment options

   DIABETES AND INSULIN IN CARDIOVASCULAR DISEASE
 

   FURTHER PERSPECTIVES
 

Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 2008 by the American Diabetes Association.